Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation

William Mccall Jordan, M. Valdivieso, C. Frankmann, M. Gillespie, B. F. Issell, G. P. Bodey, E. J. Freireich

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Sixty-five patients with extensive adenocarcinoma of the lung were treated with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP). Twenty-four received no iv hyperalimentation (IVH) (FACP alone); 19 received simultaneous IVH (S-IVH) beginning on Day 1 and continuing through the first FACP course (median, 25 days), and 22 received prechemotherapy IVH (P-IVH) beginning 10 days prior to FACP and continuing through the first course (median, 35 days). Groups were comparable except for a higher proportion of patients with less pretreatment weight loss in the group that received FACP alone. Of 48 patients with measurable disease, responses ≥ 50% were seen in 15 (4 complete and 11 partial remissions): 7 of 18 patients (39%) who received FACP alone, 2 of 13 (15%) who were given S-IVH, and 6 of 17 (35%) who received P-IVH. Of the 15 responding patients, 93% were fully active and ambulatory (class A), 87% had < 6% pretreatment weight loss, 60% were above the group median for daily nitrogen intake, and 70% were above the group median for daily caloric intake. The 40-week median survival for all patients receiving FACP alone appeared better than the median of 28 weeks for patients receiving P-IVH (P = 0.009) and 21.5 weeks for patients treated with S-IVH (P = 0.09). However, when the data were corrected for imbalances of prognostic factors, there were no differences in survival among the 3 treatment groups. Survival was prolonged in patients with < 6% pretreatment weight loss (P = 0.03), in responding patients (P = 0.01), and in patients with stable disease (P = 0.02). Five of 16 responding patients remained alive for ≥ 18 months. Protection from chemotherapy-induced gastrointestinal and hematologic toxic effects by IVH was minimal. Nutritional parameters have prognostic significance in patients with advanced adenocarcinoma of the lung. The routine use of IVH as an adjunct to chemotherapy in patients with adenocarcinoma of the lung does not appear to be justifiable.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalCancer Treatment Reports
Volume65
Issue number3-4
StatePublished - 29 Aug 1981

Fingerprint

Tegafur
Doxorubicin
Cyclophosphamide
Cisplatin
Therapeutics
Weight Loss
Adenocarcinoma of lung
Survival
Drug Therapy
Poisons
Energy Intake

Cite this

Jordan, W. M., Valdivieso, M., Frankmann, C., Gillespie, M., Issell, B. F., Bodey, G. P., & Freireich, E. J. (1981). Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. Cancer Treatment Reports, 65(3-4), 197-205.
Jordan, William Mccall ; Valdivieso, M. ; Frankmann, C. ; Gillespie, M. ; Issell, B. F. ; Bodey, G. P. ; Freireich, E. J. / Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 3-4. pp. 197-205.
@article{4ac25888574f4f2ca97c0c32b1089fd2,
title = "Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation",
abstract = "Sixty-five patients with extensive adenocarcinoma of the lung were treated with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP). Twenty-four received no iv hyperalimentation (IVH) (FACP alone); 19 received simultaneous IVH (S-IVH) beginning on Day 1 and continuing through the first FACP course (median, 25 days), and 22 received prechemotherapy IVH (P-IVH) beginning 10 days prior to FACP and continuing through the first course (median, 35 days). Groups were comparable except for a higher proportion of patients with less pretreatment weight loss in the group that received FACP alone. Of 48 patients with measurable disease, responses ≥ 50{\%} were seen in 15 (4 complete and 11 partial remissions): 7 of 18 patients (39{\%}) who received FACP alone, 2 of 13 (15{\%}) who were given S-IVH, and 6 of 17 (35{\%}) who received P-IVH. Of the 15 responding patients, 93{\%} were fully active and ambulatory (class A), 87{\%} had < 6{\%} pretreatment weight loss, 60{\%} were above the group median for daily nitrogen intake, and 70{\%} were above the group median for daily caloric intake. The 40-week median survival for all patients receiving FACP alone appeared better than the median of 28 weeks for patients receiving P-IVH (P = 0.009) and 21.5 weeks for patients treated with S-IVH (P = 0.09). However, when the data were corrected for imbalances of prognostic factors, there were no differences in survival among the 3 treatment groups. Survival was prolonged in patients with < 6{\%} pretreatment weight loss (P = 0.03), in responding patients (P = 0.01), and in patients with stable disease (P = 0.02). Five of 16 responding patients remained alive for ≥ 18 months. Protection from chemotherapy-induced gastrointestinal and hematologic toxic effects by IVH was minimal. Nutritional parameters have prognostic significance in patients with advanced adenocarcinoma of the lung. The routine use of IVH as an adjunct to chemotherapy in patients with adenocarcinoma of the lung does not appear to be justifiable.",
author = "Jordan, {William Mccall} and M. Valdivieso and C. Frankmann and M. Gillespie and Issell, {B. F.} and Bodey, {G. P.} and Freireich, {E. J.}",
year = "1981",
month = "8",
day = "29",
language = "English",
volume = "65",
pages = "197--205",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "3-4",

}

Jordan, WM, Valdivieso, M, Frankmann, C, Gillespie, M, Issell, BF, Bodey, GP & Freireich, EJ 1981, 'Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation', Cancer Treatment Reports, vol. 65, no. 3-4, pp. 197-205.

Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. / Jordan, William Mccall; Valdivieso, M.; Frankmann, C.; Gillespie, M.; Issell, B. F.; Bodey, G. P.; Freireich, E. J.

In: Cancer Treatment Reports, Vol. 65, No. 3-4, 29.08.1981, p. 197-205.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation

AU - Jordan, William Mccall

AU - Valdivieso, M.

AU - Frankmann, C.

AU - Gillespie, M.

AU - Issell, B. F.

AU - Bodey, G. P.

AU - Freireich, E. J.

PY - 1981/8/29

Y1 - 1981/8/29

N2 - Sixty-five patients with extensive adenocarcinoma of the lung were treated with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP). Twenty-four received no iv hyperalimentation (IVH) (FACP alone); 19 received simultaneous IVH (S-IVH) beginning on Day 1 and continuing through the first FACP course (median, 25 days), and 22 received prechemotherapy IVH (P-IVH) beginning 10 days prior to FACP and continuing through the first course (median, 35 days). Groups were comparable except for a higher proportion of patients with less pretreatment weight loss in the group that received FACP alone. Of 48 patients with measurable disease, responses ≥ 50% were seen in 15 (4 complete and 11 partial remissions): 7 of 18 patients (39%) who received FACP alone, 2 of 13 (15%) who were given S-IVH, and 6 of 17 (35%) who received P-IVH. Of the 15 responding patients, 93% were fully active and ambulatory (class A), 87% had < 6% pretreatment weight loss, 60% were above the group median for daily nitrogen intake, and 70% were above the group median for daily caloric intake. The 40-week median survival for all patients receiving FACP alone appeared better than the median of 28 weeks for patients receiving P-IVH (P = 0.009) and 21.5 weeks for patients treated with S-IVH (P = 0.09). However, when the data were corrected for imbalances of prognostic factors, there were no differences in survival among the 3 treatment groups. Survival was prolonged in patients with < 6% pretreatment weight loss (P = 0.03), in responding patients (P = 0.01), and in patients with stable disease (P = 0.02). Five of 16 responding patients remained alive for ≥ 18 months. Protection from chemotherapy-induced gastrointestinal and hematologic toxic effects by IVH was minimal. Nutritional parameters have prognostic significance in patients with advanced adenocarcinoma of the lung. The routine use of IVH as an adjunct to chemotherapy in patients with adenocarcinoma of the lung does not appear to be justifiable.

AB - Sixty-five patients with extensive adenocarcinoma of the lung were treated with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP). Twenty-four received no iv hyperalimentation (IVH) (FACP alone); 19 received simultaneous IVH (S-IVH) beginning on Day 1 and continuing through the first FACP course (median, 25 days), and 22 received prechemotherapy IVH (P-IVH) beginning 10 days prior to FACP and continuing through the first course (median, 35 days). Groups were comparable except for a higher proportion of patients with less pretreatment weight loss in the group that received FACP alone. Of 48 patients with measurable disease, responses ≥ 50% were seen in 15 (4 complete and 11 partial remissions): 7 of 18 patients (39%) who received FACP alone, 2 of 13 (15%) who were given S-IVH, and 6 of 17 (35%) who received P-IVH. Of the 15 responding patients, 93% were fully active and ambulatory (class A), 87% had < 6% pretreatment weight loss, 60% were above the group median for daily nitrogen intake, and 70% were above the group median for daily caloric intake. The 40-week median survival for all patients receiving FACP alone appeared better than the median of 28 weeks for patients receiving P-IVH (P = 0.009) and 21.5 weeks for patients treated with S-IVH (P = 0.09). However, when the data were corrected for imbalances of prognostic factors, there were no differences in survival among the 3 treatment groups. Survival was prolonged in patients with < 6% pretreatment weight loss (P = 0.03), in responding patients (P = 0.01), and in patients with stable disease (P = 0.02). Five of 16 responding patients remained alive for ≥ 18 months. Protection from chemotherapy-induced gastrointestinal and hematologic toxic effects by IVH was minimal. Nutritional parameters have prognostic significance in patients with advanced adenocarcinoma of the lung. The routine use of IVH as an adjunct to chemotherapy in patients with adenocarcinoma of the lung does not appear to be justifiable.

UR - http://www.scopus.com/inward/record.url?scp=0019451646&partnerID=8YFLogxK

M3 - Article

C2 - 6786737

AN - SCOPUS:0019451646

VL - 65

SP - 197

EP - 205

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 3-4

ER -